Kiadis announces presentation at the 2020 Society for Immunotherapy of Cancer Annual Meeting

Amsterdam, The Netherlands, October 26, 2020 a?? Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that a poster was accepted for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting being held virtually from November 9-14, 2020.The details of the poster presentation are as follows:

Poster #454: Oncolytic Parainfluenza Virus 5 Vector Enhances Natural Killer Cell Killing of Lung Tumor Cells in 2D and 3D spheroid cultures
Presenter: Namita Varudkar
Affiliation: University of Central Florida
Session category: Combination immunotherapies
Presentation Dates: Thursday, November 12, 4:50-5:20 p.m. EST and Saturday, November 14, 1:00-1:30 p.m. EST

All abstracts are scheduled to be available on the SITC website on November 9, 2020.Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.Dutch Translation/Nederlandse vertaling
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2021    »